A repositioning screen using an FGFR2 splicing reporter reveals compounds that regulate epithelial-mesenchymal transitions and inhibit growth of prostate cancer xenografts. (2022)

First Author: Li L
Attributed to:  Anti-angiogenic compounds based on modulation of VEGF splicing funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.omtm.2022.03.005

PubMed Identifier: 35402635

Publication URI: http://europepmc.org/abstract/MED/35402635

Type: Journal Article/Review

Volume: 25

Parent Publication: Molecular therapy. Methods & clinical development

ISSN: 2329-0501